论文部分内容阅读
以卡铂或以卡铂为主的化疗方案治疗４１９例恶性肿瘤的前瞻性Ⅲ期临床试用的结果表明：以卡铂为主的联合化疗共３６０例，对小细胞肺癌的有效率为６６．３％，对乳腺癌、食管癌及非小细胞肺癌的有效率分别为５９．３％、５５．６％和３４．１％。卡铂动脉插管化疗３８例，对原发性肝癌及其他肿瘤的有效率分别为３３．３％和５２．９％，胸腹腔恶性积液２１例的有效率为８０．９％。另有２９１例无客观疗效指标和上述的４１９例共７１０例一起观察毒性。卡铂的主要毒性反应为骨髓抑制，少数病例有一过性肝功能损害。卡铂的胃肠反应轻，对肾功能影响很小，未观察到神经及耳毒性。
The prospective phase III clinical trial of carboplatin-based or carboplatin-based regimens for the treatment of 419 malignancies showed that 360 patients treated with carboplatin-based chemotherapy had an effective rate of 66 for small cell lung cancer. 3% for breast cancer, esophageal cancer and non-small cell lung cancer were 59.3%, 55.6% and 34.1% respectively. 38 cases of carboplatin arterial intubation chemotherapy, the effective rate of primary liver cancer and other tumors were 33.3% and 52.9%, 21 cases of malignant pleural effusion, the effective rate was 80.9%. Another 291 cases of objective efficacy indicators and the above 419 cases of 710 cases together to observe the toxicity. The main toxicity of carboplatin is myelosuppression, a few cases of transient liver damage. Carboplatin gastrointestinal reaction light, little effect on renal function, no neurological and ototoxicity was observed.